Thomas Moriarity, DO
Internal Medicine · Savannah, GANPI 1669443065
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,791 of the $15,662 with a category attached, or 75.3%. It is spread thinly across 54 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $4,202 and has fallen 62.4% since, to $1,579 in 2025. Among internal medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 803 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$3K
- Boehringer Ingelheim International GmbH$2K
- Amgen$1K
- Novartis$1K
- AbbVie$838
- Novo Nordisk$751
- plus $7K from 48 others
Across 462 payments — averaging $9916.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.6M
- Modernatx, Inc.$997K
- Boehringer Ingelheim$699K
- Vertex$516K
- Organon$367K
- Novartis$160K
- plus $224K from 7 others
What the payments were for
- Speaking & faculty fees$110%
- Travel & lodging$3,79024%
- Food & beverage$11,79175%
- Education$700%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXLIZET$341
- NEXLETOL$341
- AREXVY$244
- Zevtera$135
- NURTEC ODT$128
- XARELTO$123
- TRELEGY ELLIPTA$122
- KISUNLA$112
- Repatha$107
How this compares
$15,662 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 287 | $330,432 |
| MounjaroTirzepatide | 307 | $320,705 |
| EliquisApixaban | 580 | $162,632 |
| JanuviaSitagliptin Phosphate | 401 | $131,666 |
| FarxigaDapagliflozin Propanediol | 236 | $131,590 |
| Repatha SureclickEvolocumab | 97 | $73,026 |
| TrulicityDulaglutide | 46 | $50,744 |
| JardianceEmpagliflozin | 47 | $50,420 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $49,662 |
| LinzessLinaclotide | 75 | $44,931 |
| XareltoRivaroxaban | 130 | $44,400 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $24,724 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $19,540 |
| UbrelvyUbrogepant | 16 | $17,735 |
| EntrestoSacubitril/Valsartan | 18 | $16,412 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $601 | $371,449353 claims |
| Novo NordiskOzempic | $751 | $330,432287 claims |
| PfizerEliquis | $565 | $162,632580 claims |
| MerckJanuvia, Janumet | $213 | $146,807415 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $576 | $143,536255 claims |
| Boehringer IngelheimJardiance, Tradjenta | $331 | $64,71265 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $713 | $63,00578 claims |
| AbbVieLinzess, Ubrelvy | $838 | $62,66791 claims |
| Johnson & JohnsonXarelto | $406 | $44,400130 claims |
| NovartisEntresto | $1,024 | $16,41218 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $107 | $14,77820 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $10,41140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Savannah
- Jennifer WoehlerSavannah$207K
- Timothy ConnellySavannah$50K
- John DemiccoSavannah$31K
- Paul BradleySavannah$28K
- Wilfredo DolorSavannah$17K
- Thomas HoganSavannah$17K
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.